TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01910883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 800 mg
Study: NCT02074800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328 (CHO-derived)
Description: Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328 (CHO-derived)
Description: Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
Study: NCT01910883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution
Study: NCT02074800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single-dose of matching placebo intravenously in Part 1.
Study: NCT03701685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: nerve flap
Description: sensory reconstruction via a nerve graft included in the flap
Study: NCT02410213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Study: NCT03564093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Drug
Description: 1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Drug
Description: Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
Study: NCT03848624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling Group
Description: Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
Study: NCT02322333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLD10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01494701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study: NCT03213418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
Study: NCT04170036

Intervention type: DIETARY_SUPPLEMENT
Intervention: protein supplement
Description: Protein supplement usage for at least three preceding months in varied amounts
Study: NCT02672163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG surgery
Description: Elective CABG surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG surgery
Description: Elective CABG surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AADC therapy
Description: Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
Study: NCT02044419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Study: NCT01117753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OutPatient Treatment for Adolescents (OPT-A)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Study: NCT03851913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI
Description: transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Study: NCT02008968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol 300 mg./day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normouricemic
Study: NCT01849796

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
Study: NCT00996580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-103
Description: One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE.
Study: NCT03655522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAVX-010
Description: Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There were two Placebos per group.
Study: NCT00450515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT01910883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution
Study: NCT04034316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord-blood mesenchymal stromal cells
Description: The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
Study: NCT00082095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
Study: NCT02609373

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep intervention
Description: Session 1: Intervener \& participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 \& 10 months: reinforcement, question answering, encouragement and monitoring.
Study: NCT04006678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided sandwich osteotomy
Description: segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: computer guided sandwich osteotomy
Description: segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
Study: NCT02333266

Intervention type: OTHER
Intervention: Candidemia
Study: NCT03184506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre-warming
Description: On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no warming
Description: patients were covered only with two layers of cotton blanket
Study: NCT01028612

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thermal ablation with external beam radiation
Description: thermal ablation with external beam radiation
Study: NCT04195347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620
Description: IV
Study: NCT01096498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Description: Single dose of one 0.75 mg coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (Postday)
Description: Single dose of one 0.75 mg tablet
Study: NCT03290183

Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Real-time microscopic imaging technique
Study: NCT04250428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand intervention
Description: Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supply intervention
Description: In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
Study: NCT00719940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: 1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waiting group
Description: No intervention
Study: NCT04054726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial pulsed current stimulation (tPCS)
Description: Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial pulsed current stimulation (tPCS)
Description: Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
Study: NCT02743065

Intervention type: DEVICE
Intervention: HepaSphere with 50-75mg Doxorubicin
Description: HepaSphere with 50-75mg Doxorubicin
Study: NCT04616040

Intervention type: DRUG
Intervention: Camrelizumab
Description: The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
Study: NCT03832673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
Study: NCT02783313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pathogen reduced plasma-stored platelet concentrates
Description: Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-stored platelet concentrates
Description: Platelet concentrates stored in plasma
Study: NCT00496587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 800 mg/m\^2 By Mouth Twice Daily On Days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg By Vein On Days 1 and 15.
Study: NCT00822328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult®300
Description: Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yakult®300
Description: Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota
Description: Lactobacillus casei strain Shirota
Study: NCT01937884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Study: NCT00674895

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT01415375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Screening Education
Description: tailored telephone education on prostate cancer testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fruit and Vegetable Intake Education
Description: tailored telephone education about fruit and vegetable consumption
Study: NCT02008006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM
Description: High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0
Study: NCT00495859

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition
Description: food for special medical purpose (FSMP)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food for special medical purposes (FSMP)
Description: an isocaloric isonitrogenous non-specific nutritional support
Study: NCT00005796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: GCSF is given after chemo administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gene therapy
Description: stem cells are collected and given back to the patients after chemotherapy adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: chemotherapy is administered every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: chemotherapy is administered every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: chemotherapy is administered every 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: stem cells are reinfused after chemotherapy administration
Study: NCT02806830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optive
Description: Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
Study: NCT03158610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral fluorouracil
Study: NCT01690299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablet orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg evaluator/subject-blinded SC QW injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablets BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablets BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
Study: NCT04956939

Intervention type: DRUG
Intervention: Low dose levodopa
Description: Low frequency is defined as ≤ 3 LD doses a day

Intervention type: DRUG
Intervention: High dose levodopa
Description: High frequency dosage is defined as ≥ 5 LD doses per day
Study: NCT01588405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR
Description: Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
Study: NCT03706469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T2
Description: TAK-831 T2 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T2
Description: TAK-831 T2 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T2
Description: TAK-831 T2 Tablets.
Study: NCT02542098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYD tablets
Description: Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
Study: NCT03667664

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy
Description: * Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~* Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people.